recent newsUpdated warning on counterfeit Alli dosing
The FDA is updating its warning about a counterfeit version of Alli (orlistat caps, from GlaxoSmithKline) that does not contain orlistat, rather sibutramine Fake Alli Pills Putting Dieters in DangerCounterfeit Alli Prompts FDA WarningMeridia, Alli and Xenical: Popular Diet Drugs in the Safety...
recent newsGSK and eBay team up to fight fake Alli
GlaxoSmithKline has joined forces with eBay to try to remove online auctions peddling fake versions of its Alli weight loss drug, according to a report on GSK Works With eBay to Stop Online Counterfeit Alli Salesall 2 news articles »
recent newsThe bigger picture
The drug still prescribed for weight loss, orlistat, can also be bought over the counter at a different dosage, as Alli. Both orlistat and Reductil reduce and more »
recent newsalli may help reduce dangerous fat
Washington, Jan 28 (ANI): Taking alli (orlistat 60 mg) with a reduced calorie, lower-fat diet can lead to a significant reduction not only in weight but alli Proven to Reduce Visceral Fat, a Dangerous Fat Linked to Many Life Weight loss drug alli could reduce dangerous diabetes fatNew Research...
recent newsBlood pressure: weight loss
who lost modest amounts of weight through diet alone, or diet plus the "fat-blocker" orlistat (Xenical, Alli), did experience blood pressure drops. and more »
Posted by admin on 10 29, 09 |
No Comments For a drug to become FDA approved it must go through rigorous testing, first on animals, then later in a series of human clinical trials (You can read more about each phase of the process in drug development .
But an initial FDA approval does not guarantee that a drug won’t later be found unsafe as more people take it and use it over a longer periods of time. This has happened to a host of obesity drugs that have been approved and sold, only to be taken off the market later; well known examples of this are amphetamines and Fen-phen.
In the case of orlistat, a red flag has been raised by the FDA. In late August 2009, a notice was issued to healthcare professionals and those taking the drug communicating that a safety review was being conducted. Thirty-two liver-related injuries had been reported in patients using the drug since 1999, indicating the potential for a serious health risk. While the most common complaints were jaundice, weakness and abdominal pain, there were six cases of liver failure.
tastymistake says:
FastNWL says:
HideJackyle says:
rachaelcollens says:
Flipcell says:
